Article
Efficacy and safety of bilastine in Japanese patients with chronic spontaneous urticaria: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II/III study.
Allergology international : official journal of the Japanese Society of Allergology - 1 Apr 2017
Hide Michihiro, Yagami Akiko, Togawa Michinori, Saito Akihiro, Furue Masutaka
Abstract excerpt
BACKGROUND: Bilastine, a novel non-sedating second-generation H1-antihistamine, has been widely used in the treatment of allergic rhinoconjunctivitis and urticaria with a recommended dose of 20 mg once daily in most European countries since 2010. We evaluated its efficacy and safety in Japanese patients with chronic spontaneous urticaria (CSU). METHODS: We conducted a multicenter, randomized, double-blind,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.